The results of a large Phase-III clinical trial confirm.

The Phase-III trial included 1195 patients from 13 countries whose metastatic, castration-resistant prostate cancer had previously been treated with 1 of 2 chemotherapeutic agents that included docetaxel. Among the 398 sufferers assigned to get the corticosteroid prednisone plus placebo randomly, median overall survival was 10.9 months. Among the 797 who received abiraterone prednisone plus acetate, median survival was 14.8 months.‘ The display will be delivered at 4:30 p.m. EST on Wednesday Nov. 10, in the abstract session titled ‘Rheumatoid Arthritis Treatment – Small Molecules, Biologics and Gene Therapy: Novel Compounds III.’ Related StoriesArthritis increases risk of dropping into poverty, fresh research showsImmune system protein has potential to prevent onset of aggressive type of rheumatoid arthritisRheumatoid arthritis considerably increases threat of death because of cardiovascular causesData from a Stage 1 clinical research of a subcutaneous formulation of ALD518 will be provided in a poster titled ‘Safety, Pharmacokinetics and Pharmacodynamics of ALD518 , a High-Affinity Monoclonal Antibody Directed Against Interleukin-6 Administered by Subcutaneous Injection: A Stage I Trial.’ The poster, 1124, will be offered by Sepehr Shakib, M.D., director of pharmacology at Royal Adelaide Medical center in Adelaide, Australia, in poster session B.

You Might Also Like